Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

University of California, Davis

ClinicalTrials.gov lists University of California, Davis as lead sponsor of 808 trials. It has 274 active development programs and 171 approved assets.

US Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

77 0 1995 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 47 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 44 in 2026 and about 44 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 47 already registered with a 2026 start date: at the cutoff, 14 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Logo Original University of California seal: probably Tiffany & Co,; This SVG file: Casecrer, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers University of California, Davis: 808 lead-sponsored trials and 1 legal-entity registration. The parent company on record for University of California, Davis is University of California System, which does not have its own page on this site.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the University of California, Davis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (481)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Disease areas
Disease area Trials
Obesity 46
Diabetes Mellitus 40
Malnutrition 37
Lung Neoplasms 32
Pain 28

Trials by start year as sponsor or collaborator (30)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 47
2025 45
2024 44
2023 67
2022 52
2021 69
2020 48
2019 55
2018 51
2017 77

Prediction, not a registry value: median of 36 months from start to primary completion across 100 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 586 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (274)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Oral Oxybutynin Urinary Bladder, Neurogenic Phase 3 1
Oxybutynin Transdermal Patch Urinary Bladder, Neurogenic Phase 3 1
Rituximab combined with Omalizumab Pemphigoid, Bullous Phase 3 1
Transnasal Sphenopalatine ganglion block Headache Phase 2/3 1
Transnasal Sphenopalatine ganglion block Hemorrhage Phase 2/3 1

Approved assets (171)

Shown in this order: max phase first.

Approved assets
Drug Trials
Gabapentin 3
Acetaminophen 2
Etonogestrel contraceptive implant 2
Zinc Supplement 2
ZINC 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
44% hit target (n=294) 45% on time (n=288)

CLIA clinical laboratory certificates (2)

Shown in this order: active first, then certificate type.

CLIA clinical laboratory certificates
Lab Certificate Status
UC DAVIS Certificate for PPM procedures Active
UNIVERSITY OF CALIFORNIA DAVIS Certificate of waiver Active

Biomarker capability evidence (730)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCB1 Trial collaborator Named in trial inclusion criteria
ABCD1 Trial sponsor Named in trial inclusion criteria
AGA Trial collaborator Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.

Counted at group level under University of California System: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.